InMed Pharmaceuticals (INM) Income towards Parent Company (2021 - 2026)

InMed Pharmaceuticals has reported Income towards Parent Company for 6 years, with the latest figure at -$174585.0 in Q1 2026.

• For the quarter ending Q1 2026, Income towards Parent Company fell 224.14% year-over-year to -$174585.0; the trailing twelve-month figure through Mar 2026 stood at -$5.2 million (up 16.05% YoY), and the FY2025 full-year result was -$8.2 million, down 6.34% from the prior year.
• Income towards Parent Company for Q1 2026 stood at -$174585.0, up from -$2.0 million in the prior quarter.
• The five-year high for Income towards Parent Company was -$53861.0 in Q1 2025, with the low at -$7.9 million in Q2 2022.
• Historically, Income towards Parent Company has averaged -$2.1 million across 5 years, with a median of -$1.9 million in 2024.
• Annual changes were most pronounced in 2024 — Income towards Parent Company tumbled 473.57% — and 2025, when it surged 96.87%.
• InMed Pharmaceuticals' Income towards Parent Company stood at -$2.1 million in 2022, then advanced by 29.55% to -$1.5 million in 2023, then slumped by 74.2% to -$2.6 million in 2024, then advanced by 21.23% to -$2.0 million in 2025, then soared by 91.39% to -$174585.0 in 2026.
• The last three Income towards Parent Company figures came in at -$174585.0 (Q1 2026), -$2.0 million (Q4 2025), and -$1.7 million (Q3 2025), per Business Quant data.